“Shift Toward Biologic and Targeted Immunomodulatory Therapies”
A key trend in the Asia-Pacific Dry Eye Syndrome Treatment market is the growing adoption of biologic agents and targeted therapies, particularly for cases associated with autoimmune conditions and chronic inflammatory diseases that are unresponsive to conventional corticosteroids. The region is increasingly focusing on TNF-alpha inhibitors, IL-6 antagonists, and T-cell modulators to manage inflammation at the molecular level with higher precision.
-
For instance, adalimumab, a TNF-alpha inhibitor, has seen expanded use in several Asia-Pacific countries for non-infectious intermediate and posterior uveitis, offering prolonged remission and fewer relapses.
-
The integration of optical coherence tomography (OCT), AI-based diagnostic tools, and personalized medicine platforms is optimizing disease monitoring and therapeutic decisions.
Additionally, advancements in long-acting ocular drug delivery systems, including depot formulations and intraocular implants, are significantly enhancing patient adherence and minimizing systemic adverse effects.
